Viking seen ‘holding up’ against obesity competition as Roche presents data - InvestingChannel

Viking seen ‘holding up’ against obesity competition as Roche presents data

Shares of Viking Therapeutics (VKTX) are in the spotlight on Thursday after Roche (RHHBY) announced results from Genentech’s Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. While acknowledging that… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3920546/-Viking-seen-holding-up-against-obesity-competition-as-Roche-presents-data)

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire